Emergent's Trubion buyout clears regulatory hurdle
[AP] - The planned buyout of Trubion Pharmaceuticals Inc. by Emergent BioSolutions Inc. cleared a regulatory hurdle Wednesday, bringing the deal, potentially worth $135.5 million, closer to closing.

EMERGENT BIOSOLUTIONS INC. Files SEC form 8-K, Other Events

Emergent and Trubion say US clears acquisition
[AP] - Emergent BioSolutions Inc. said Wednesday that antitrust regulators cleared its acquisition of Trubion Pharmaceuticals Inc.

Emergent BioSolutions Announces Early Termination of HSR Waiting Period for Its Acquisition of Trubion Pharmaceuticals
[Business Wire] - ROCKVILLE, Md.----Emergent BioSolutions Inc. announced today that the U.S. Department of Justice and Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 , as amended, with respect to the planned acquisition of Trubion Pharmaceuticals, Inc. by Emergent BioSolutions announced on August 12, 2010.

Trubion Pharmaceuticals Announces Early Termination of HSR Waiting Period
[PR Newswire] - Trubion Pharmaceuticals, Inc. today announced that the U.S. Department of Justice and Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 , as amended, with respect to the planned acquisition of Trubion by Emergent BioSolutions Inc. announced on Aug. 12, 2010.

Emergent BioSolutions Announces Commencement of Phase I Clinical Trial for Monoclonal Antibody to Treat Inhalational Anthrax
[Business Wire] - ROCKVILLE, Md.----Emergent BioSolutions Inc. announced today that the Phase I clinical trial for its anthrax monoclonal antibody therapeutic has commenced with the dosing of the first subject.

China Biotech Week in Review: New IPO

EMERGENT BIOSOLUTIONS INC. Files SEC form 8-K, Change in Directors or Principal Officers